# OTR Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/otr-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.otr-tx.com
- Total disclosed funding: $100M
- Latest round: Series A (Jun 30, 2025)
- Investors on record: 4

## About

Founded in 2025 and based in Shanghai, China, Shanghai Aolu Biomedical Technology Co., Ltd., trading as OTR Therapeutics, is a service provider in the research and experimental development sector, specializing in biopharmaceutical-related businesses. In June 2025, OTR Therapeutics raised USD 100 million in Series A funding from new investors True Light Capital, Pfizer Venture Investments, Lilly Asia Ventures and Sirona Capital.
The company specializes in developing novel therapeutics for metabolic diseases, focusing on catalyzing early innovation into impactful global therapies. The company's core offerings include advanced biologics and small molecule therapeutics aimed at addressing various metabolic disorders.
The company generates revenue through strategic collaborations and licensing agreements, reflecting a partnership-oriented business model. 
The company will use the funding to support the further development of its pipeline and services.

## Funding rounds

- Series A, Jun 30, 2025, $100M — Lilly Asia Ventures, Pfizer Venture Investments, True Light Capital, Sirona Capital Partners Ltd.

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- True Light Capital (https://capitalatlas.ai/funds/true-light-capital) — Series A
- Sirona Capital Partners Ltd. — Series A